


## Update

8 October 2015

### Key Statistics

Code	: OPTI
Listing	: AIM
Sector	: Biotechnology
Market Cap	: £29.2m
Share in issue	: 73.7m
Current Price	: 48p
12 mnth High/Low	: 50p/8.875p

### Stock Performance



Source: Fidessa

### Financials (y/e Dec)

Cash balance as at May 2015: £2.5m

Source: H1 results

### Company description

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease. OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

### HYBRIDAN LLP

20 Ironmonger Lane, London, EC2V 8EP  
Website: [www.hybridan.com](http://www.hybridan.com)

Derren Nathan  
Tel: 020 3764 2344  
Email: [derren.nathan@hybridan.com](mailto:derren.nathan@hybridan.com)

## IP asset base continues to strengthen

The life sciences business developing compounds to tackle obesity, high cholesterol and diabetes has this week announced that it has registered an additional five proprietary microbial strains (now a total of eight) under the Budapest treaty. The five strains have been identified as having the potential to generate novel oligosaccharides (carbohydrates that consist of a small number of sugars). As OptiBiotix advances its programmes towards commercialisation it is vital that its know-how, microbial strains and processes are protected, thereby strengthening the negotiating position with partners. The oligosaccharides programme is being progressed in conjunction with the Spanish National Research Council and is moving towards the commencement of human studies in 2016.

Strain registration protects ownership and allows OptiBiotix to build application patents around specific strains creating valuable assets. In any commercial deal ownership of a strain linked to its registration and deposit in an international repository is critical.

- Comes soon after the completion of human studies on the cholesterol product which is now undergoing pilot manufacturing studies.
- Adds to IP portfolio. Since IPO the company has expanded the number of patents filed from five to nine.
- Share price performance has been strong up 26.6% over the quarter reflecting ongoing commercial and scientific progress.
- Our risked valuation at initiation in February applied a 75% risk discount generating a theoretical valuation of 48.9p. The company is now arguably significantly closer to commercialisation. On an illustrative basis a reduction of the risk discount to 70% generates an indicative value of 56.4p per share which rises to 65.4p at 65%.
- Of course the financial terms of future any commercial partnerships will be the true value drivers, but strong IP and scientific advances will strengthen OptiBiotix's position at the bargaining table with well-resourced companies who may be keen to exploit this novel approach to human health.

Last month OptiBiotix announced that the human studies for its cholesterol targeting microbial based supplement were complete. However under the terms of an option agreement with a multinational consumer goods company the results of the study were embargoed under strict confidentiality clauses which is common practice by blue chip organisations in order to protect their competitive position.

Nonetheless we can take comfort in that OptiBiotix has commenced pilot manufacturing studies to define the scale up requirements to take the strain from laboratory to pilot scale manufacture, an indication of its confidence of the product's commercial viability. Importantly this strain is one of the three that were already registered.

As well as strain registrations OptiBiotix has been increasing its patent portfolio (as per the 28 May announcement) and has now filed a total of nine patents surrounding its platforms' abilities to identify metabolic pathways and compounds that impact on human physiology. The registration of additional microbial strains increases the likelihood of further patent filings.

The OptiBiotix share price has continued to perform well up 26.6% in the last quarter. Indeed since our initiation the company has made significant strides in terms of scientific progress, accumulation of intellectual property, a strategic alliance, a completed human study and an option agreement with a multinational company over its rapidly advancing cholesterol programme. Data thus far suggests safety and tolerance and manufacturing studies are underway. At the time of our initiation in February we prepared an indicative valuation of the company whereby we applied a 75% risk discount reflecting the relative early stage of the company's programmes generating an indicative value per share of 48.9p. Given the progress the company has made we argue that the risks associated with commercialising OptiBiotix's multiple programmes (and in due course developing additional programmes) has reduced.

Adjusting for dilutive shares in issue even a modest five percentage point reduction to 70% in the risk discount has the effect of increasing the indicative value per share (per our model) to 56.4p. At a still relatively conservative 65% risk weighting our model suggests a value of 65.4p per share. Investors will naturally be focusing on the monetary value of potential deals, in terms of up-front payments, milestones and royalties, which are of course the tangible outcome of value crystallisation. However as the science, innovation and IP progresses in the background, this continually strengthens OptiBiotix's position at the bargaining table with well-resourced companies who may be keen to exploit this novel approach to human health.

**Income Statement**

	6 months to 31 May 2015 Unaudited £	6 months to 31 May 2014 Unaudited £	Year to 30 November 2014 Audited £
<b>Continuing operations</b>			
Administrative expenses	(514,431)	(57,643)	(489,015)
<b>Operating loss</b>	(514,431)	(57,643)	(489,015)
<b>Non-Operating Items</b>			
Admission expenses	-	-	(365,038)
Finance income / (costs)	7	-	93
<b>Loss before Income tax</b>	(514,424)	(57,643)	(853,960)
Income tax	-	-	43,254
<b>Loss for the period</b>	(514,424)	(57,643)	(810,706)
<b>Total comprehensive income for the period</b>	(514,424)	(57,643)	(810,706)
Total comprehensive income attributable to the owners of the company	(514,424)	(57,643)	(810,706)
<b>Loss per share</b>			
Basic & Diluted loss per share - pence	0.708p	1.144p	3.03p

*Source: OptiBiotix Health PLC Half Year Report*

**Cashflow Statement**

	6 months to 31 May 2015 Unaudited £	6 months to 31 May 2014 Unaudited £	Year to 30 November 2014 Audited £
<b>Reconciliation of loss before income tax to cash outflow from operations</b>			
Operating loss	(565,284)	(57,643)	(854,053)
(Increase)/decrease in trade and other receivables	(23,944)	291,233	296,616
Decrease in trade and other payables	(24,507)	(201,548)	(212,913)
Share Option expense	127,728	-	63,770
Depreciation	347	-	244
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Net cash outflow from operations</b>	(485,660)	32,042	(706,336)
Interest paid	-	-	-
Interest received	7	-	93
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Net cash outflow from operating activities</b>	(485,653)	32,042	(706,243)
<b>Cash flows from investing activities</b>			
Purchases of property, plant and equipment	(1,965)	-	(1,099)
Net cash from acquisition of subsidiary	-	-	251,834
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Net cash (outflow)/inflow from investing activities</b>	(1,965)	-	250,735
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Cash flows from financing activities</b>			
Share issues	87,753	73,029	3,300,068
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Net cash inflow from financing activities</b>	87,753	73,029	3,300,068
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Taxation</b>	-	-	25,732
<b>Increase/(decrease) in cash and equivalents</b>	(399,865)	105,071	2,870,292
Cash and cash equivalents at beginning of year	2,870,442	150	150
	<u>          </u>	<u>          </u>	<u>          </u>
Cash and cash equivalents at end of year	<u>2,470,577</u>	<u>105,221</u>	<u>2,870,442</u>

Source: OptiBiotix Health PLC Half Year Report

## Balance Sheet

	As at 31 May 2015 Unaudited	As at 31 May 2014 Unaudited	As at 30 November 2014 Audited
	£	£	£
<b>ASSETS</b>			
<b>Non-current assets</b>			
Intangibles	2,259,369	-	2,259,369
Property, plant & equipment	2,473	-	855
	<u>2,261,842</u>	<u>-</u>	<u>2,260,224</u>
<b>CURRENT ASSETS</b>			
Trade and other receivables	28,595	10,034	4,651
Current tax asset	94,107	-	43,254
Cash and cash equivalents	2,470,577	105,221	2,870,442
	<u>2,593,279</u>	<u>115,255</u>	<u>2,918,347</u>
<b>TOTAL ASSETS</b>	<u><u>4,855,121</u></u>	<u><u>115,255</u></u>	<u><u>5,178,571</u></u>
<b>EQUITY</b>			
<b>Shareholders' Equity</b>			
Called up share capital	7,100,284	5,742,586	7,078,346
Share premium	3,812,596	1,355,502	3,746,781
Share based payment reserve	218,698	27,200	90,970
Merger relief reserve	1,500,000	-	1,500,000
Accumulated deficit	(8,281,437)	(7,013,950)	(7,767,013)
<b>Total Equity</b>	<u>4,350,141</u>	<u>111,338</u>	<u>4,649,084</u>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Trade and other payables	53,106	3,917	77,613
	<u>53,106</u>	<u>3,917</u>	<u>77,613</u>
<b>Non - current liabilities</b>			
Deferred tax	451,874	-	451,874
	<u>451,874</u>	<u>-</u>	<u>451,874</u>
<b>TOTAL LIABILITITES</b>	<u>504,980</u>	<u>3,917</u>	<u>529,487</u>
<b>TOTAL EQUITY AND LIABILITIES</b>	<u>4,855,121</u>	<u>115,255</u>	<u>5,178,571</u>

---

---

---

*Source:*

*OptiBiotix Health PLC Half Year Report*

**Research Disclaimer**

This document should not be relied upon as being an impartial or objective assessment of the subject matter and is not deemed to be "independent research" for the purposes of the Financial Conduct Authority rules. As a consequence the research (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research (although Hybridan does impose restrictions on personal account dealing in the run up to publishing research as set out in our Conflicts of Interest Policy).

Hybridan LLP is involved in providing other financial services to Optibiotix Health plc (the "Company") and as a result Hybridan LLP may have responsibilities that conflict with the interests of the persons who receive this document.

This document has been issued by Hybridan LLP for **information purposes only** and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity. Hybridan LLP and/or connected persons may, from time to time, effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. The information contained herein is based on materials and sources that we believe to be reliable, however, Hybridan LLP makes no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Opinions expressed are our current opinions as of the date appearing on this material only. Any opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. None of Hybridan LLP, its affiliates or employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from any use of this document.

In the UK, this report is directed at and is for distribution only to persons who (i) fall within Article 19(1) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties of Hybridan LLP (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied upon by persons in the UK who are not relevant persons.

Neither this report nor any copy or part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Investments in general involve some degree of risk, including the risk of capital loss. The services, securities and investments discussed in this document may not be available to or suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment advisor. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where investment is made in currencies other than the investor's base currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable. Levels and bases for taxation may change. When Hybridan LLP comments on AIM or ISDX Markets shares investors should be aware that because the rules for those markets are less demanding than the Official List of the London Stock Exchange the risks are higher. Furthermore, the marketability of these shares is often restricted.

Hybridan LLP and/or its associated companies may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the partners, directors and employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is Authorised and Regulated by the Financial Conduct Authority and is a member of the London Stock Exchange.

Hybridan LLP

20 Ironmonger Lane, London, EC2V 8EP

T +44 (0) 20 3764 2341, F +44 (0) 20 7600 1586

[www.hybridan.com](http://www.hybridan.com)

**Hybridan LLP**

**Research Disclosures**

Investment analyst certification:

All research is issued under the regulatory oversight of Hybridan LLP. Each Investment Analyst of Hybridan LLP whose name appears as the Author of this Investment Research hereby certifies that the opinions expressed in the Investment Research accurately reflect the Investment Analyst's personal and objective views about any and all of the companies or the Company discussed herein that are within such Investment Analyst's coverage universe.

The Investment Analyst who is responsible for the preparation of this Investment Research is an employee of Hybridan that has been engaged by Hybridan LLP to produce this document.

Investment Research Disclosures:

1. Hybridan LLP may receive compensation for Corporate Finance services from this Company in the next twelve months.
2. Hybridan LLP acts as Corporate Broker for the Company.
3. Hybridan may provide investment banking services to the Company and in that capacity may have received confidential information relevant to the securities mentioned in this research report which is not known to the researcher who has compiled this research report.

Hybridan, its partners, officers or employees or any connected persons may at the time of publication have an interest in the equity of the Company through the holding of warrants, securities, futures, options, derivatives and any other financial instrument of any of the companies referred to in this document. Hybridan at the time of publication currently has no interest of this nature in the Company discussed herein. If exercised this interest would not be required to be notified as it would comprise less than 3% of the Company's issued share capital. Hybridan reserves the right to increase or dispose of this interest and / or the underlying shares resulting from exercise, without further notice. Any disposal or acquisition of warrants or shares will be undertaken under the FCA guidelines regarding Closed Periods and Public Disclosure as required.

Research recommendations:

In line with our conflicts of interest policy Hybridan LLP does not produce recommendations or publish target prices on companies who are corporate clients of Hybridan LLP.